InvestSMART

Emyria Limited (ASX: EMD) - Announcements

- Current share price for EMD : $0.047

ASX company news and announcements for Emyria Limited (EMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Emyria Limited (EMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Emyria Limited (EMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Emyria Limited (EMD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$38 Investor Presentation 23 Nov 2022 9:55AM $0.185 $0.047 fallen by 74.59%
$38 Notification regarding unquoted securities - EMD 23 Nov 2022 9:37AM $0.185 $0.047 fallen by 74.59%
$38 Application for quotation of securities - EMD 23 Nov 2022 9:34AM $0.185 $0.047 fallen by 74.59%
$38 Notification of cessation of securities - EMD 18 Nov 2022 6:57PM $0.185 $0.047 fallen by 74.59%
$38 Amended Constitution 17 Nov 2022 10:36AM $0.190 $0.047 fallen by 75.26%
$38 Appendix 4C - Quarterly 31 Oct 2022 2:53PM $0.215 $0.047 fallen by 78.14%
$38 Proposed issue of securities - EMD 31 Oct 2022 10:11AM $0.210 $0.047 fallen by 77.62%
$38 Proposed issue of securities - EMD 31 Oct 2022 10:11AM $0.210 $0.047 fallen by 77.62%
$38 Proposed issue of securities - EMD 31 Oct 2022 10:11AM $0.210 $0.047 fallen by 77.62%
$38 Emyria completes $3m placement 31 Oct 2022 10:11AM $0.210 $0.047 fallen by 77.62%
$38 Trading Halt 27 Oct 2022 9:39AM $0.210 $0.047 fallen by 77.62%
$38 Results of Meeting 25 Oct 2022 3:24PM $0.200 $0.047 fallen by 76.50%
$38 Emyria and UWA expand unique MDMA-inspired analogue library 18 Oct 2022 9:03AM $0.215 $0.047 fallen by 78.14%
$38 MDMA-inspired drug discovery presentation 13 Oct 2022 9:43AM $0.215 $0.047 fallen by 78.14%
$38 Emyria Investor Webinar - October 13 10 Oct 2022 9:31AM $0.220 $0.047 fallen by 78.64%
$38 Emyria expands clinical sites for EMD-RX5 Phase 3 trial 26 Sep 2022 8:18AM $0.225 $0.047 fallen by 79.11%
$38 Letter to Shareholders - Annual General Meeting 23 Sep 2022 5:45PM $0.225 $0.047 fallen by 79.11%
$38 Notice of Annual General Meeting/Proxy Form 23 Sep 2022 5:43PM $0.225 $0.047 fallen by 79.11%
$38 Emyria commences US preclinical program for MDMA library 19 Sep 2022 9:50AM $0.225 $0.047 fallen by 79.11%
$38 Annual General Meeting 31 Aug 2022 9:35AM $0.255 $0.047 fallen by 81.57%
$38 Annual Report to Shareholders 30 Aug 2022 10:47AM $0.255 $0.047 fallen by 81.57%
$38 Appendix 4G 29 Aug 2022 6:55PM $0.255 $0.047 fallen by 81.57%
$38 Appendix 4E and Annual Report 29 Aug 2022 6:55PM $0.255 $0.047 fallen by 81.57%
$38 Positive results received for Emyrias MDMA-inspired program 18 Aug 2022 9:27AM $0.255 $0.047 fallen by 81.57%
$38 Notification regarding unquoted securities - EMD 17 Aug 2022 7:27PM $0.255 $0.047 fallen by 81.57%

301 - 325 of 554 results

Page 13 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.